Routinely available indicators of prognosis in breast cancer

Breast Cancer Research and Treatment

Volumn 51, Issue 3, 1998, Pages 195-208

  Page, David L ^a   Jensen, Roy A ^a,b   Simpson, Jean F ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Histology; Pathology; Prognosis; Tumor grade; Tumor type

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

AXILLARY LYMPH NODE; BIOCHEMISTRY; BREAST CANCER; CANCER GRADING; CARCINOMA IN SITU; CELL PROLIFERATION; DISEASE SEVERITY; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LYMPH NODE; MITOSIS INDEX; PATHOLOGY; PATIENT CARE; PRIORITY JOURNAL; REVIEW; TUMOR CLASSIFICATION; TUMOR NECROSIS; TUMOR VOLUME;

BREAST NEOPLASMS; DIAGNOSTIC TESTS, ROUTINE; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032441650     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006122716137     Document Type: Review

References (123)

1. Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, O'Sullivan B, Sobin LH, Yarbro JW: AJCC Cancer Staging Manual (5th ed). Lippincott-Raven, Philadelphia, 1997
2. Page DL: Prognosis and breast cancer - Recognition of lethal and favorable prognostic types. Am J Surg Pathol 15:334-349, 1991
3. Rosen PP, Groshen S, Saigo P, Kinne DW, Hellman S: A long-term follow-up study of survival in Stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 7:355-366, 1989
4. Simpson JF, Page DL: The role of pathology in premalignancy and as a guide for treatment and prognosis in breast cancer. Semin Oncol 23:428-435, 1996
5. Dorr FA: Prognostic factors observed in current clinical trials. Cancer 71:2163-2168, 1993
6. Roberti NE: The role of histologic grading in the prognosis of patients with carcinoma of the breast - Is this a neglected opportunity? Cancer 80:1708-1716, 1997
7. Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, Winn RJ: Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88:1456-1466, 1996
8. Gasparini G, Pozza F, Harris AL: Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85:1206-1219, 1993
9. Sloane JP, Anderson TJ, Davies JD, Ellis IO, Elston CW, Millis RR, Wells CA (for the National Coordinating Committee for Breast Screening Pathology): Pathology reporting in breast cancer screening. National Health Service Breast Screening Programme, Sheffield, UK, 1995
10. Henson DE, Fielding LP, Grignon DJ, Page DL, Hammond ME, Nash G, Pettigrew NM, Gorstein F, Hutter RV, for the Cancer Committee C: College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Summary. Arch Pathol Lab Med 119:1109-1112, 1995
11. Connolly JL, Fechner RE, Kempson RL, Livolsi VA, Page DL, Patchefsky AA, Silverberg SG, for ADASP: Recommendations for the reporting of breast carcinoma. Hum Pathol 27:220-224, 1996
12. Wells WA, Carney PA, Eliassen MS, Tosteson AN, Greenberg ER: Statewide study of diagnostic agreement in breast pathology. J Natl Cancer Inst 90 (in press)
13. Page DL, Jensen RA, Simpson JF: Premalignant and malignant disease of the breast. The role of the pathologist. Mod Pathol Feb 1998 (in press)
14. Page DL, Dupont WD, Jensen RA, Simpson JF: When and to what end do pathologists agree? J Natl Cancer Inst 90 (in press)
15. Dalton LW, Page DL, Dupont WD: Histologic grading of breast carcinoma. A reproducibility study. Cancer 73:2765-2770, 1994
16. Baak JP: Mitosis counting in tumors. Hum Pathol 21:683-685, 1990
17. Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW: Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 20:479-489, 1992
18. Page DL, Anderson TJ: How should we categorize breast cancer? The Breast 2:217-219, 1993
19. Pereira H, Pinder SE, Sibbering DM, Galea MH, Elston CW, Blamey RW, Robertson J, Ellis IO: Pathological prognostic factors in breast cancer. IV. Should you be a typer of a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology 27:219-226, 1995
20. Simpson JF, Page DL: Prognostic value of histopathology in the breast. Semin Oncol 19:254-262, 1992
21. Pinder SE, Ellis IO, Elston CW: Prognostic factors in primary breast carcinoma. J Clin Pathol 48:981-983, 1995
22. Jensen ML, Kiaer H, Andersen J, Jensen V, Melsen F: Prognostic comparison of three classifications for medullary carcinomas of the breast. Histopathology 30:523-532, 1997
23. Elston CW, Ellis IO: Method for grading breast cancer. J Clin Pathol 46:189-190, 1993
24. Koscielny S, Tubiana M, Le MG, Valleron AJ, Mouriesse H, Contesso G, Sarrazin D: Breast cancer relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer 49:709-715, 1984
25. Tubiana M, Pejovic MJ, Renaud A, Contesso G, Chavaudra N, Gioanni J, Malaise EP: Kinetic parameters and the course of the disease in breast cancer. Cancer 47:937-943, 1981
26. Silvestrini R, Daidone MG, Luisi A, Boracchi P, Mezzetti M, Di Fronzo G, Andreola S, Salvadori B, Veronesi U: Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol 13:697-704, 1995
27. Fisher ER, Gregorio RM, Fisher B: The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (Protocol no 4). Cancer 36:1-85, 1975
28. Holland PA, Walls J, Boggis CR, Knox F, Baildam AD, Bundred NJ: A comparison of axillary node status between cancers detected at the prevalence and first incidence breast screening rounds. Br J Cancer 74:1643-1646, 1996
29. Dixon JM, Page DL, Anderson TJ, Lee D, Elton RA, Stewart HJ, Forrest AP: Long-term survivors after breast cancer. Br J Surg 72:445-448, 1985
30. Gallager HS: Pathologic types of breast cancer: their prognoses. Cancer 53:623-629, 1984
31. Dixon JM, Anderson TJ, Page DL, Lee D, Duffy SW: Infiltrating lobular carcinoma of the breast. Histopathol 6:149-161, 1982
32. du Toit RS, Locker AP, Ellis IO, Elston CW, Nicholson RI, Blamey RW: Invasive lobular carcinomas of the breast - the prognosis of histopathological subtypes. Br J Cancer 60:605-609, 1989
33. Toikkanen S, Pylkkanen L, Joensuu H: Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br J Cancer 76:1234-1240, 1997
34. Knorr KL, Hilsenbeck SG, Wenger CR, Pounds G, Oldaker T, Vendely P, Pandian MR, Harrington D, Clark GM: Making the most of your prognostic factors. Presenting a more accurate survival model for breast cancer patients. Breast Cancer Res Treat 22:251-262, 1992
35. Henson DE, Fielding LP, Grignon DJ, Page DL, Hammond ME, Nash G, Pettigrew NM, Gorstein F, Hutter RV, for the Cancer Committee CAP: College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Arch Pathol Lab Med 119:1109-1112, 1995
36. Sauerbrei W, Hubner K, Schmoor C, Schumacher M: Validation of existing and development of new prognostic classification schemes in node negative breast cancer. Breast Cancer Res Treat 42:149-163, 1997
37. Goldhirsch A, Wood WC, Seen H-J, Glick JH, Gelber RD: International consensus panel on the treatment of primary breast cancer. Eur J Can 31A:1754-1759, 1995
38. Veronesi U, Zurrida S: Breast cancer surgery a century after Halsted [review]. J Cancer Res Clin Oncol 122:74-77, 1996
39. Hermanek P, Sobin LH, Fleming ID: What do we need beyond TNM? Cancer 77:815-817, 1996
40. Galea MH, Blamey RW, Elston CE, Ellis IO: The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22:207-219, 1992
41. Robertson JFR, Dixon AR, Nicholson RI, Ellis IO, Elston CW, Blamey RW: Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy. Breast Cancer Res Treat 22:221-227, 1992
42. Barbareschi M, Caffo O, Veronese S, Leek RD, Fina P, Fox S, Bonzanini M, Girlando S, Morelli L, Eccher C, Pezzella F, Doglioni C, Dalla Palma P, Harris A: Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Hum Pathol 27:1149-1155, 1996
43. Schnitt SJ, Abner A, Gelman R, Connolly JL, Recht A, Duda RB, Eberlein TJ, Mayzel K, Silver B, Harris JR: The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy. Cancer 74:1746-1751, 1994
44. Connolly JL, Harris JR, Schnitt SJ: Understanding the distribution of cancer within the breast is important for optimizing breast-conserving treatment. Cancer 76:1-3, 1995
45. Schnitt SJ, Hayman J, Gelman R, Eberlein TJ, Love SM, Mayzel K, Osteen RT, Nixon AJ, Pierce S, Connolly JL, Cohen P, Schneider L, Silver B, Recht A, Harris JR: A prospective study of conservative surgery alone in the treatment of selected patients with stage I breast cancer. Cancer 77:1094-1100, 1996
46. Veronesi U, Marubini E, Del Vecchio M, Manzari A, Andreola S, Greco M, Luini A, Merson M, Saccozzi R, Rilke F, Salvadori B: Local recurrences and distant metastases after conservative breast cancer treatments: Partly independent events. J Natl Cancer Inst 87:19-27, 1995
47. Nixon AJ, Schnitt SJ, Gelman R, Gage I, Bornstein B, Hetelekidis S, Recht A, Silver B, Harris JR, Connolly JL: Relationship of tumor grade to other pathologic features and to treatment outcome of patients with early stage breast carcinoma treated with breast-conserving therapy. Cancer 781426-1431, 1996
48. Amesson L-G, Hatschek T, Smeds S, Grontoft O: Histopathology grading in small breast cancers <10mm - results from an area with mammography screening. Breast Cancer Res Treat 44:39-46, 1997
49. Lee AKC, Loda M, Mackarem G, Bosari S, DeLellis RA, Heatley GJ, Hughes K: Lymph node negative invasive breast carcinoma I centimeter or less in size (T1aN0M0): clinicopathologic features and outcome. Cancer 76:761-771, 1996
50. Chadha M, Chabon AB, Friedmann P, Vikram B: Predictors of axillary lymph node metastases in patients with TI breast cancer: a multivariate analysis. Cancer 73:350-353, 1994
51. Miller WR, Ellis IO, Sainsbury J, Dixon JM: ABC of breast diseases: Prognostic factors. Br Med J 309:1573-1576, 1994
52. Mansour EG, Ravdin PM, Dressler L: Prognostic factors in early breast carcinoma. Cancer 74:381-400, 1994
53. Seidman JD, Schnaper LA, Aisner SC: Relationship of the size of the invasive component of the primary breast carcinoma to axillary lymph node metastasis. Cancer 75:65-71, 1995
54. Balslev I, Axelsson CK, Zedeler K, Rasmussen BB, Carstensen B, Mouridsen HT: The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast Cancer Res Treat 32:281-290, 1994
55. Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases. Cancer 63:181-187, 1989
56. Henson DE: Cancer patient staging: a perspective. Arch Pathol Lab Med 115:120-121, 1991
57. Kollias J, Elston CE, Ellis IO, Robertson JFR, Blamey RW: Early-onset breast cancer - histopathological and prognostic considerations. Br J Cancer 75:1318-1323, 1997
58. Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP, Blamey RW, Haybittle JL: Confirmation of a prognostic index in primary breast cancer. Br J Cancer 56:489-492, 1987
59. Ambros RA, Trost RC: Cellularity in breast carcinoma. Am J Clin Pathol 93:98-100, 1990
60. Collan YU, Eskelinen MJ, Nordling SA, Lipponen P, Pesonen E, Kumpusalo LM, Pajarinen P, Kettunen KO: Prognostic studies in breast cancer - Multivariate combination of nodal status, proliferation index, tumor size, and DNA ploidy. Acta Oncol 33:873-878, 1994
61. Quiet CA, Ferguson DJ, Weichselbaum RR, Hellman S: Natural history of node-positive breast cancer: the curability of small cancers with a limited number of positive nodes. J Clin Oncology 14:3105-3111, 1996
62. Van Bogaert L-J: Immunohistochemical detection and significance of axillary lymph node micrometastases in breast carcinoma. Analyt Quant Cytol Histol 17:75-76, 1995
63. Siegel RJ: Surgical pathology of lymph nodes in cancer staging routine and specialized techniques [review]. Surg Oncol Clin N Am 5:25-31, 1996
64. de Mascarel I, Bonichon F, Coindre JM, Trojani M: Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. Br J Cancer 66:523-527, 1992
65. Donegan WL, Stine SB, Samter TG: Implications of extracapsular nodal metastases for treatment and prognosis of breast cancer. Cancer 72:778-782, 1993
66. Anderson TJ, Lamb J, Alexander F, Lutz W, Chetty U, Forrest AP, Kirkpatrick A, Muir B, Roberts MM, Huggins A: Comparative pathology of prevalent and incident cancers detected by breast screening. Lancet 1:519-522, 1986
67. Carriaga MT, Henson DE: The histologic grading of cancer. Cancer 75:406-421, 1995
68. Contesso G, Mouriesse H, Friedman S, Genin J, Sarrazin D, Rouesse J: The importance of histologic grade in long-term prognosis of breast cancer: A study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy. J Clin Oncol 5:1378-1386, 1987
69. Simpson JF, Page DL: The role of pathology in premalignancy and as a guide for treatment and prognosis in breast cancer. Semin Oncol 23:428-435, 1996
70. Simpson JF, Page DL: Status of breast cancer prognostication based on histopathologic data. Am J Clin Pathol 102:S3-S8, 1994
71. Pinder SE, Wencyk P, Sibbering DM, Bell JA, Elston CW, Nicholson R, Robertson J, Blamey RW, Ellis IO: Assessment of the new proliferation marker MIBI in breast carcinoma using image analysis: Associations with other prognostic factors and survival. Br J Cancer 71:146-149, 1995
72. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term followup. Histopathol 19:403-410, 1991
73. Frierson HF Jr, Wolber RA, Berean KW, Franquemont DW, Gaffey MJ, Boyd JC, Wilbur DC: Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol 103:195-198, 1995
74. Anderson TJ, Page DL: Risk assessment in breast cancer. In: Anthony PP, MacSween RNM, Lowe DG (eds) Recent Advances in Histopathology, Vol. 17. Churchill Livingstone, Edinburgh, 1997, pp 69-91
75. Frierson HF Jr, Wolber RA, Berean KW, Franquemont DW, Gaffey MJ, Boyd JC, WiLbur DC: Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol 103:195-198, 1995
76. Contesso G, Jotti GS, Bonadonna G: Tumor grade as a prognostic factor in primary breast cancer [review]. Eur J Cancer Clin Oncol 25:403-409, 1989
77. Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M: Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR): An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 64:1914-1921, 1989
78. Cooper HS, Patchefsky AS, Krall RA: Tubular carcinoma of the breast. Cancer 42:2334-2342, 1978
79. McDivitt RW, Boyce W, Gersell D: Tubular carcinoma of the breast: clinical and pathological observations concerning 135 cases. Am J Surg Pathol 6:401-411, 1982
80. Page DL, Dixon JM, Anderson TJ, Lee D, Stewart HJ: Invasive cribriform carcinoma of the breast. Histopathol 7:525-536, 1983
81. Parl FF, Richardson LD: The histological and biological spectrum of tubular carcinoma of the breast. Hum Pathol 14:694-698, 1983
82. Venable JG, Schwartz AM, Silverberg SG: Infiltrating cribriform carcinoma of the breast: a distinctive clinicopathologic entity. Hum Pathol 21:333-338, 1990
83. Wheeler JE, Enterline HT: Lobular carcinoma of the breast in situ and infiltrating. In: Sommers SC (ed) Pathology Annual, Vol 11, 1976, pp 161-188
84. Martinez V, Azzopardi JG: Invasive lobular carcinoma of the breast: incidence and variants. Histopathology 3:467-488, 1979
85. Dixon AR, Ellis IO, Elston CW, Blamey RW: A comparison of the clinical metastatic patterns of invasive lobular and ductal carcinomas of the breast. Br J Cancer 63:634-635, 1991
86. Borst MJ, Ingold JA: Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. Surgery 114:637-641, 1993
87. du Toit RS, Locker AP, Ellis IO, Elston CW, Nicholson RI, Robertson JF, Blamey RW: An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. Eur J Surg Oncol 17:251-257, 1991
88. Holland PA, Shah A, Howell A, Baildam AD, Bundred NJ: Lobular carcinoma of the breast can be managed by breast-conserving therapy. Br J Surg 82:1364-1366, 1995
89. Jain S, Fisher C, Smith P, Millis RR, Rubens RD: Patterns of metastatic breast cancer in relation to histological type. Eur J Cancer 15:2155-2157, 1993
90. Kidney DD, Cohen AJ, Butler J: Abdominal metastases of infiltrating lobular breast carcinoma: CT and fluoroscopic imaging findings. Abdominal Imaging 22:156-159, 1997
91. Lamovec J, Bracko M: Metastatic pattern of infiltrating lobular carcinoma of the breast: an autopsy study. J Surg Oncol 48:28-33, 1991
92. Taal BG, den Hartog Jager FC, Steinmetz R, Peterse H: The spectrum of gastrointestinal metastases of breast carcinoma. I. Stomach. Gastrointestinal Endoscopy 38:130-135, 1992
93. Weidner N, Semple JP: Pleomorphic variant of invasive lobular carcinoma of the breast. Hum Pathol 23:1167-1171, 1992
94. Eusebi V, Magalhaes F, Azzopardi JG: Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation. Hum Pathol 23:655-662, 1992
95. Pedersen L, Holck S, Schiodt T, Zedeler K, Mouridsen HT: Medullary carcinoma of the breast, prognostic importance of characteristic histopathological features evaluated in a multivariate Cox analysis. Eur J Cancer 30A:1792-1797, 1994
96. Ridolfi RL, Rosen PP, Post A, Kinne T, Mike V: Medullary carcinoma of the breast. A clinical pathological study with 10 year follow-up. Cancer 40:1365-1385, 1977
97. Pedersen L, Zedeler K, Holck S, Schiodt T, Mouridsen HT: Medullary carcinoma of the breast, proposal for a new simplified histopathological definition. Br J Cancer 63:591-595, 1991
98. Rapin V, Contesso G, Mouriesse H, Bertin F, Lacombe MJ, Piekarski JD, Travagli JP, Gadenne C, Friedman S: Medullary breast carcinoma. A reevaluation of 95 cases of breast cancer with inflammatory stroma. Cancer 61:2503-2510, 1988
99. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, Linder-Stephenson L, Salerno G, Conway TA, Lynch HT: Hereditary breast cancer: pathobiology, prognosis, and BRCAI and BRCA2 gene linkage. Cancer 77:697-709, 1996
100. Clayton F: Pure mucinous carcinomas of breast: Morphologic features and prognostic correlates. Hum Pathol 17:34-38, 1986
101. Rosen PP, Lesser ML, Kinne DW: Breast carcinoma at the extremes of age: a comparison of patients younger than 35 years and older than 75 years. J Surg Oncol 2890-96, 1985
102. Fentiman IS, Millis RR, Smith P, Ellul JPM, Lampejo O: Mucoid breast carcinomas: Histology and prognosis. Br J Cancer 75:1061-1065, 1997
103. Silvestrini R, Daidone MG, Mastore M, Di Fronzo G, Coradini D, Boracchi P, Squicciarini P, Salvadori B, Veronesi U: Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy. J Clin Oncol 11:1150-1155, 1993
104. 3H-thymidine labelling index. Int J Cancer 74:122-127, 1997
105. van Diest PJ, Baak JPA, Matze-Cok P, Wisse-Brekelmans ECM, Van Galen CM, Kurver PHJ, Bellot SM, Fijnheer J, Van Gorp LHM, Kwee WS, Los J, Peterse JL, Ruitenberg HM, Schapers RFM, Schipper MEI, Somsen JC, Willig A, Ariens AT: Reproducibility of mitosis counting in 2,469 breast cancer specimens: Results from the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol 23:603-607, 1992
106. Page DL, Simpson JF: Measures of proliferation in breast cancer: practicality and utility. The Breast 6:169-170, 1997
107. Connor AJM, Pinder SE, Elston CW, Bell JA, Wencyk P, Robertson JFR, Blamey RW, Nicholson RI, Ellis IO: Intratumoral heterogeneity of proliferation in invasive breast cancer evaluated with MIB1 antibody. The Breast 6:171-176, 1997
108. Jannink I, Risberg B, Van Diest PJ, Baak JP: Heterogeneity of mitotic activity in breast cancer. Histopathology 29:421-428, 1996
109. Simpson JF, Dutt PL, Page DL: Expression of mitoses per thousand cells and cell density in breast carcinoma: a proposal. Hum Pathol 23:608-611, 1992
110. Baak JPA, Van Dop H, Kurver PHJ, Hermans J: The value of morphometry to classic prognosticators in breast cancer. Cancer 56:374-382, 1985
111. Pinder SE, Wencyk P, Sibbering DM, Bell JA, Elston CW, Robertson JF, Nicholson R, Blamey RW, Ellis IO: Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 71:146-149, 1995
112. Rudas M, Gnant M, Mittlböck M, Neumayer R, Kummer A, Jakesz R, Reiner G, Reiner A: Thymidine labeling index and Ki-67 growth fraction in breast cancer. Breast Cancer Res Treat 32:165-175, 1994
113. Ellis PA, Makris A, Burton SA, Titley J, Ormerod MG, Salter J, Powles TJ, Smith IE, Dowsett M: Comparison of MIB-1 proliferation index with S-phase fraction in human breast carcinomas. Br J Cancer 73:640-643, 1996
114. Simpson JF, Page DL: Cellular proliferation and prognosis in breast cancer: statistical purity versus clinical utility [editorial]. Hum Pathol 25:331-332, 1994
115. Keshgegian AA, Cnaan A: Proliferation markers in breast carcinoma: Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol 104:42-49, 1995
116. Leong AS-Y, Lee AKC: Biological indices in the assessment of breast cancer. J Clin Pathol Mol Pathol 48:M221-M238, 1995
117. Molino A, Micciolo R, Turazza M, Bonetti F, Piubello Q, Corgnati A, Sperotto L, Recaldin E, Spagnolli P, Manfrin E, Bonetti A, Nortilli R, Tomezzoli A, Pollini GP, Modena S, Cetto GL: Prognostic significance of estrogen receptors in 405 primary breast cancers: a comparison of immunohistochemical and biochemical methods. Breast Cancer Res Treat 45:241-249, 1997
118. Esteban JM, Ahn C, Battifora H, Felder B: Quantitative immunohistochemical assay for hormonal receptors: technical aspects and biological significance. J Cell Biochem 19,S:138-145, 1994
119. Esteban JM, Ahn C, Battifora H, Felder B: Predictive value of estrogen receptors evaluated by quantitative immunohistochemical analysis in breast cancer. Am J Clin Pathol 102:S9-12, 1994
120. Parl FF, Posey YF: Discrepancies of the biochemical and immunohistochemical estrogen receptor assays in breast cancer. Hum Pathol 19:960-966, 1988
121. Davis BW, Gelber R, Goldhirsch A, Hartmann WH, Hollaway L, Russell I, Rudenstam CM: Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Hum Pathol 16:1212-1218, 1985
122. Lee AK, DeLellis RA, Wolfe HJ: Intramammary lymphatic invasion in breast carcinomas. Evaluation using ABH isoantigens as endothelial markers. Am J Surg Pathol 10:589-594, 1986
123. Lee AK, DeLellis RA, Silverman ML, Wolfe HJ: Lymphatic and blood vessel invasion in breast carcinoma: a useful prognostic indicator? Hum Pathol 17:984-987, 1986